{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Pan H"],"funding":["National Center for Advancing Translational Sciences","NCATS NIH HHS","NIA NIH HHS","Michael J. Fox Foundation for Parkinson's Research","National Institute of General Medical Sciences","National Institute on Aging","NIGMS NIH HHS","Michael J. Fox Foundation for Parkinson's Research"],"pagination":["88"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12019173"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["11(1)"],"pubmed_abstract":["Aggregation of the protein α-synuclein (α-syn) is the histopathological hallmark of neurodegenerative diseases such as Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA), which are collectively known as synucleinopathies. Currently, patients with synucleinopathies are diagnosed by physical examination and medical history, often at advanced stages of disease. Because synucleinopathies are associated with α-syn aggregates, and α-syn aggregation often precedes onset of symptoms, detecting α-syn aggregates would be a valuable early diagnostic for patients with synucleinopathies. Here, we design a liganded magnetic nanoparticle (LMNP) functionalized with an α-syn-targeting peptide to be used as a magnetic resonance imaging (MRI)-based biomarker for α-sy"],"journal":["NPJ Parkinson's disease"],"pubmed_title":["Liganded magnetic nanoparticles for magnetic resonance imaging of α-synuclein."],"pmcid":["PMC12019173"],"funding_grant_id":["MJFF-005905","T32 GM008042","UL1TR001881","1F30AG077832-01A1","T32 GM008496","UL1 TR001881","MJFF-001065","F30 AG077832"],"pubmed_authors":["Eisenberg DS","Shahpasand-Kroner H","Frautschy SA","Zuo X","Williams CK","Vinters HV","Mekkittikul M","Cheng X","Denver P","Hu CJ","Jacobs RE","Sta Maria NS","Lepore S","Abskharon R","Sawaya MR","Harris NG","Cole GM","Balbirnie M","Zhu C","Mirbaha H","Pan H","Jones M","Hou K","Sahay S","Lu J"],"additional_accession":[]},"is_claimable":false,"name":"Liganded magnetic nanoparticles for magnetic resonance imaging of α-synuclein.","description":"Aggregation of the protein α-synuclein (α-syn) is the histopathological hallmark of neurodegenerative diseases such as Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA), which are collectively known as synucleinopathies. Currently, patients with synucleinopathies are diagnosed by physical examination and medical history, often at advanced stages of disease. Because synucleinopathies are associated with α-syn aggregates, and α-syn aggregation often precedes onset of symptoms, detecting α-syn aggregates would be a valuable early diagnostic for patients with synucleinopathies. Here, we design a liganded magnetic nanoparticle (LMNP) functionalized with an α-syn-targeting peptide to be used as a magnetic resonance imaging (MRI)-based biomarker for α-sy","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Apr","modification":"2025-07-10T03:08:57.412Z","creation":"2025-07-10T03:08:57.412Z"},"accession":"S-EPMC12019173","cross_references":{"pubmed":["40268938"],"doi":["10.1038/s41531-025-00918-z"]}}